Mutations in chikungunya virus nsP4 decrease viral fitness and sensitivity to the broad-spectrum antiviral 4′-Fluorouridine
PLOS Pathogens · 13.01.2025 · 21 (1) · e1012859
DOI: 10.1371/journal.ppat.1012859 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 13.01.2025. Verfasst von Peiqi Yin und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, United States of America. Hauptthemen laut MEDLINE: Chikungunya virus, Antiviral Agents, Viral Nonstructural Proteins, Chikungunya Fever. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Chikungunya virus (CHIKV) is an arthritogenic alphavirus that has re-emerged to cause large outbreaks of human infections worldwide. There are currently no approved antivirals for treatment of CHIKV infection. Recently, we reported that the ribonucleoside analog 4′-fluorouridine (4′-FlU) is a highly potent inhibitor of CHIKV replication, and targets the viral nsP4 RNA dependent RNA polymerase. In mouse models, oral therapy with 4′-FlU diminished viral tissue burdens and virus-induced disease signs. To provide critical evidence for the potential of 4′-FlU as a CHIKV antiviral, here we selected for CHIKV variants with decreased 4′-FlU sensitivity, identifying two pairs of mutations in nsP2 and nsP4. The nsP4 mutations Q192L and C483Y were predominantly responsible for reduced sensitivity. These variants were still inhibited by higher concentrations of 4′-FlU, and the mutations did not change nsP4 fidelity or provide a virus fitness advantage in vitro or in vivo. Pathogenesis studies in mice showed that the nsP4-C483Y variant caused similar disease and viral tissue burden as WT CHIKV, while the nsP4-Q192L variant was strongly attenuated. Together these results support the potential of 4′-FlU to be an important antiviral against CHIKV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cell Biology, Albert Einstein College of Medicine, Bronx, New York, United States of America.
- Virology Division, Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Washington, United States of America.
- Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, Colorado, United States of America.
- Institute of Bioengineering, University of Tartu, Tartu, Estonia.
ORCID-Profile: Peiqi Yin, Andres Merits, Thomas E Morrison, Alexander L Greninger, Margaret Kielian
Förderung
- NCI NIH HHS
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Yin, P., Sobolik, E. B., May, N. A., Wang, S., Fayed, A., Vyshenska, D., Drobish, A. M., Parks, M. G., Lello, L. S., Merits, A., Morrison, T. E., Greninger, A. L., & Kielian, M. (2025). Mutations in chikungunya virus nsP4 decrease viral fitness and sensitivity to the broad-spectrum antiviral 4′-Fluorouridine. PLOS Pathogens, 21(1), e1012859. https://doi.org/10.1371/journal.ppat.1012859
Vancouver
Yin P, Sobolik EB, May NA, Wang S, Fayed A, Vyshenska D, et al. Mutations in chikungunya virus nsP4 decrease viral fitness and sensitivity to the broad-spectrum antiviral 4′-Fluorouridine. PLOS Pathogens. 2025;21(1):e1012859. doi:10.1371/journal.ppat.1012859
BibTeX
@article{Yin2025,
author = {Yin, Peiqi and Sobolik, Elizabeth B and May, Nicholas A and Wang, Sainan and Fayed, Atef and Vyshenska, Dariia and Drobish, Adam M and Parks, M Guston and Lello, Laura Sandra and Merits, Andres and Morrison, Thomas E and Greninger, Alexander L and Kielian, Margaret},
title = {Mutations in chikungunya virus nsP4 decrease viral fitness and sensitivity to the broad-spectrum antiviral 4′-Fluorouridine},
journal = {PLOS Pathogens},
year = {2025},
volume = {21},
number = {1},
pages = {e1012859},
doi = {10.1371/journal.ppat.1012859}
}
EUVIMED